- Home
- AVDL
as 03-07-2025 4:00pm EST
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.
| Founded: | 2015 | Country: | Ireland |
| Employees: | 188 | City: | DUBLIN |
| Market Cap: | 764.3M | IPO Year: | 1996 |
| Target Price: | $18.86 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.51 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.39 - $19.09 | Next Earning Date: | 03-03-2025 |
| Revenue: | $169,117,000 | Revenue Growth: | 504.79% |
| Revenue Growth (this year): | 51.49% | Revenue Growth (next year): | 32.18% |
Stock Insider Trading Activity of Avadel Pharmaceuticals plc (AVDL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Palczuk Linda | AVDL | Director | Jan 21 '25 | Buy | $7.93 | 5,000 | $39,640.00 | 67,900 | |
| Ende Eric J | AVDL | Director | Jan 13 '25 | Buy | $7.84 | 30,000 | $235,218.00 | 208,900 | |
| Thornton Peter J. | AVDL | Director | Jan 13 '25 | Buy | $8.05 | 10,000 | $80,450.00 | 104,055 | |
| MCHUGH THOMAS S | AVDL | Chief Financial Officer | Dec 13 '24 | Buy | $10.44 | 2,300 | $24,018.67 | 87,800 | |
| MCHUGH THOMAS S | AVDL | Chief Financial Officer | Dec 11 '24 | Buy | $10.49 | 5,000 | $52,432.50 | 87,800 | |
| Glass Geoffrey Michael | AVDL | Director | Dec 10 '24 | Buy | $9.85 | 20,279 | $199,640.95 | 69,075 |
Latest Avadel Pharmaceuticals plc News
AVDL Breaking Stock News: Dive into AVDL Ticker-Specific Updates for Smart Investing
Argus Research
2 days ago
Daily – Vickers Top Insider Picks for 03/07/2025
Argus Research
3 days ago
Daily – Vickers Top Insider Picks for 03/06/2025
GlobeNewswire
4 days ago
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
Argus Research
4 days ago
Daily – Vickers Top Insider Picks for 03/05/2025
MT Newswires
5 days ago
Deutsche Bank Adjusts Avadel Pharmaceuticals Price Target to $13 From $12, Maintains Buy Rating
Argus Research
5 days ago
Daily – Vickers Top Insider Picks for 03/04/2025
Simply Wall St.
5 days ago
Avadel Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations
GuruFocus.com
5 days ago
Avadel Pharmaceuticals PLC (AVDL) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...
Compare AVDL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AVDL Avadel Pharmaceuticals plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.